Key facts
- It has raised $10.9M.
- Notable investors include High-Tech Gründerfonds, FS Life Science Investment, CARMA FUND Management, GIMIC Ventures, Marathon Beteiligungs — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for WMT
- ·The full record, as it builds
Funding rounds
No funding rounds for WMT are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About WMT
Operator of a drug discovery company intended to develop selective translational inhibition therapies for cancer and inflammatory diseases operating in the pharmaceutical research domain. The company offers small-molecule drug candidates that target the protein translation process to selectively inhibit fast-proliferating cancer cells, overactive immune cells, and virus-infected cells, with development programs focused on blood cancers, chronic inflammatory autoimmune disorders such as rheumatoid arthritis, and viral infections, enabling clinicians and researchers to pursue targeted treatments with reduced impact on healthy cells.
- Sector
- Healthcare
- HQ
- Heidelberg, Germany
- Founded
- 2020
- Employees
- 14
- Website
- wm-therapeutics.com/
- Ownership
- Privately Held (backing)
WMT doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in WMT shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on WMT in its N-PORT filings yet. We sweep new filings monthly.